Introduction: Attention deficit hyperactivity disorder (ADHD) is the most prevalent neurobiological condition affecting children and adolescents. Treatment with methylphenidate is increasing and evidence-based guidelines are lacking regarding the maximum dose to be used in titration. This study aims to determine the evidence base for the maximum doses used in clinical trials and the adverse effects of methylphenidate during dose titration.
given for choice of doses used in 5 out of 27 studies but none cited definitive scientific evidence in support. Analysis of randomised controlled trials show 1.55 increased risk (CI = 1.08-2.22; P = 0.02) of adverse events in treatment groups compared to controls, with 4.66-increased risk of insomnia (CI = 1.99-10.92; P = 0.00) and 5.11-increased risk of anorexia (CI = 1.99-13.14; P = 0.00a). Case studies showed an overall adverse event rate of 63% (CI = 51-74%; P = 0.03), with headaches at 16% (CI = 12-23%; P = 0.00), anorexia 27% (CI = 17-41%; P = 0.00) and insomnia 16% (CI 10-23%; P = 0.00).
Conclusion and Relevance:
This meta-analysis demonstrates a disturbing lack of evidence supporting any specified maximum dose of methylphenidate. Further studies should investigate the efficacy and safety of methylphenidate titrated to clinical effect without a set maximum dosage. University of NSW, Sydney, NSW, Australia Introduction: Urinary incontinence is common in childhood, 1 and impacts on self-esteem and quality of life, which improves with successful treatment. 2 However, there is perceived unwarranted variation in clinical practice in the management of childhood urinary incontinence among health professionals. The aim of our study was to survey Australian community health practitioners about their experience and knowledge in managing childhood urinary incontinence to determine the educational needs and resources required to serve this group. Methods: Health professionals on the Healthed (a private health education organisation) database who have registered to receive regular education updates and educational surveys were invited to participate in an online survey. The questionnaire asked questions relating to their experience, knowledge and confidence in managing urinary incontinence that begins in childhood and what they would use as first-line therapy for these conditions. Participants' response to questions about firstline management of childhood incontinence was compared with their previous experience, practice discipline and practice setting. Demographics were described by frequencies and percentages. Associations between participant demographics and responses to treatment questions were examined using chisquare tests.
Results: In total 1495 clinicians completed the survey, with a response rate of 8.6% (1495/17 361). Most respondents (84%) were female, 70% were aged 45 years and above, 78% had 10 or more years in clinic practice and 69% practiced in a metropolitan area. Most (67%) were doctors, and 30% were nurses.
Most respondents (88%) reported being knowledgeable about managing bedwetting in childhood and 75% reported being knowledgeable about daytime wetting. Only 37% reported being knowledgeable about adult bedwetting that began in childhood. When asked about what they thought the first-line therapy for childhood bedwetting was, only 49% chose enuresis alarm training, 8% would use desmopressin, 3% would use anticholinergics and 2% would use tricyclics.
When asked about what they thought the first-line therapy for daytime wetting was, 7% chose an enuresis alarm, 8% chose desmopressin, 7% chose anticholinergics and 2% chose tricyclics.
Conclusions: The management of childhood urinary incontinence among Australian community health professionals is variable, with inappropriate and dangerous practices 3 such as using bedwetting alarms and desmopressin for treating daytime urinary incontinence and a reluctance to use appropriate treatments such as enuresis alarm training for bedwetting, indicating a need for professional development.
